Instil Bio, Inc. - 10-Q Filing
Instil Bio, Inc. reports Q3 2026 financial results including restructuring costs and asset impairment charges related to building construction.
Tickers: $TIL
Read the full article at SEC EDGAR
Part of the story FMC Reports Significant Third Quarter Losses Driven by Pricing Restructuring and Inventory Adjustments (6 articles)